There are significant regional differences in patient characteristics and risk profiles among European patients with atrial fibrillation, though oral anticoagulation use remains relatively consistent across regions.
No takes yet. Share an insight, caveat, or question.
Uniform OAC use despite regional CHA2DS2-VASc differences supports outcome studies; leaves open questions on appropriateness and equity.
Lip et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: